Bone-targeted, nonpeptide inhibitors of the Src SH2 domain: Structure-based design and structure-activity relationships

Regine S. Bohacek(Ariadne Diagnostics (United States)), Tomi K. Sawyer(Merck & Co., Inc., Rahway, NJ, USA (United States)), David C. Dalgarno(New Jersey Urology), Wei Guan(Guangzhou Experimental Station), D. T. Johnson(Memorial Hermann), Ruth Yuan(Ariadne Diagnostics (United States)), Craig S. Takeuchi(Ariadne Diagnostics (United States)), Shelia M. Violette(Biogen (United States)), Marcos Hatada(Ariadne Diagnostics (United States)), William C. Shakespeare(Ariadne Diagnostics (United States)), Charles J. Eyermann(Ariadne Diagnostics (United States)), Chad A. Haraldson(Ariadne Diagnostics (United States)), Catherine Bartlett(Ariadne Diagnostics (United States)), Surinder S. Narula(Ariadne Diagnostics (United States)), Virginia A. Jacobsen(Ariadne Diagnostics (United States)), Frank Cerasoli(Ariadne Diagnostics (United States)), Vaibhav Varkhedkar(Ariadne Diagnostics (United States)), Noriyuki Kawahata(Ariadne Diagnostics (United States)), Karin J. Stebbins(Ariadne Diagnostics (United States)), Jeremy A. Smith(Ariadne Diagnostics (United States)), Susan K. Wood(University of South Carolina System), Karina J. Macek(Ariadne Diagnostics (United States)), Chester A. Metcalf(Ariadne Diagnostics (United States)), Yihan Wang(Boston Medical Center), Ping Li(Tongji Hospital), Xiaode Lu(Ariadne Diagnostics (United States)), George P. Luke(Ariadne Diagnostics (United States)), Raji Sundaramoorthi(Ariadne Diagnostics (United States)), Ian A. MacNeil(Acuity Technologies (United States)), Manfred Weigele(La Roche College), Marie Rose van Schravendijk(Ariadne Diagnostics (United States)), Berkley A. Lynch(UCB Pharma (Belgium)), Michael G. Yang(University of Pittsburgh)
Unknown
January 1, 2002
Cited by 0


Related Papers